Selected Adverse Reactions in S. aureus Bacteremia

  • The most clinically significant adverse reactions observed with CUBICIN® (daptomycin for injection) 4 mg/kg (cSSSI trials) and 6 mg/kg (S. aureus bacteremia/endocarditis trial) were abnormal liver function tests, elevated CPK, and dyspnea
  • Discontinuation rates due to adverse reactions in the S. aureus bacteremia/endocarditis trial were similar between the CUBICIN and comparator arm (17% and 18%, respectively)

Incidence of adverse reactions that occurred in 5% of patients in the CUBICIN treatment group and ≥ the comparator treatment group in the S. aureus bacteremia/endocarditis trial

Event NUMBER OF PATIENTS (%)
CUBICIN (n=120) Comparatora (n=116)
Sepsis NOS 6 (5%) 3 (3%)
Bacteremia 6 (5%) 0 (0%)
Abdominal pain NOS 7 (6%) 4 (3%)
Chest pain 8 (7%) 7 (6%)
Edema NOS 8 (7%) 5 (4%)
Pharyngolaryngeal pain 10 (8%) 2 (2%)
Pruritus 7 (6%) 6 (5%)
Sweating increased 6 (5%) 0 (0%)
Insomnia 11 (9%) 8 (7%)
Blood CPK increased 8 (7%) 1 (1%)
Hypertension NOS 7 (6%) 3 (3%)
  1. Vancomycin or semisynthetic penicillin, each with initial gentamicin.

  • CUBICIN® (daptomycin for injection) has an established adverse reaction profile in patients treated up to 28 days; there are limited data beyond 28 days

Learn about the adverse reaction profile of CUBICIN in patients with cSSSI. »